◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

IOVANCE BIOTHERAPEUTICS, INC.

CIK: 1425205 SIC: 2836
$263.50M
Revenue
$-390.98M
Net Income
28.66%
Gross Margin
-153.08%
Op. Margin
$-630.96M
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 7 of 41 quarterly reports available
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
+ Total Revenue $86.77M $67.45M $59.95M $49.32M $73.69M $58.55M $31.11M
Revenue Growth % (YoY) 17.7% 15.2% 92.7% nan% nan% nan% nan%
Cost of Revenue $43.11M $38.48M $56.66M $49.74M $37.79M $39.82M $31.37M
+ Gross Profit $43.66M $28.98M $3.29M $-417.00K $35.91M $18.73M $-262.00K
Gross Margin % 50.3% 43.0% 5.5% -0.8% 48.7% 32.0% -0.8%
Operating Expenses $160.23M $162.36M $173.73M $170.54M $160.27M $147.62M $133.02M
Research & Development $71.20M $75.17M $79.36M $76.88M $71.01M $68.25M $62.08M
+ Operating Income $-73.46M $-94.90M $-113.77M $-121.22M $-86.58M $-89.07M $-101.91M
Operating Margin % -84.7% -140.7% -189.8% -245.8% -117.5% -152.1% -327.6%
Interest Income $1.74M $1.24M $4.10M $3.22M $9.57M $4.00M $3.35M
Income Before Tax $-71.72M $-93.66M $-109.67M $-118.00M $-77.00M $-85.06M $-98.56M
Income Tax Expense $184.00K $-2.40M $1.99M $-1.84M $1.56M $-1.52M $-1.46M
+ Net Income $-71.90M $-91.25M $-111.66M $-116.16M $-78.56M $-83.54M $-97.10M
Net Margin % -82.9% -135.3% -186.2% -235.5% -106.6% -142.7% -312.2%
Basic EPS -0.15 -0.25 -0.33 -0.36 -0.25 -0.28 -0.34
Diluted EPS nan nan -0.33 -0.36 -0.25 -0.28 -0.34
Basic Shares Outstanding - 364K 335K 323K 5K 303K 285K
Diluted Shares Outstanding - - 335K 323K 5K 303K 285K
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $163.08M $158.13M $132.47M $171.67M $115.69M $164.19M $228.68M
Short-term Investments $133.90M $142.67M $168.71M $188.04M $208.09M $233.30M $183.86M
Accounts Receivable $82.45M $66.76M $59.94M $70.94M $69.34M $55.77M $31.60M
Inventory $51.68M $51.71M $49.83M $65.55M $51.52M $38.58M $27.85M
Other Current Assets $11.58M $9.82M $11.55M $15.89M $12.38M $6.74M $10.18M
Total Current Assets $442.69M $429.09M $422.50M $512.65M $457.02M $498.58M $482.26M
Property Plant & Equipment $131.11M $126.65M $122.47M $111.58M $109.08M $112.52M $110.96M
Intangible Assets $279.32M $285.21M $296.25M $285.36M $282.40M $306.64M $295.30M
Other Non-current Assets $8.17M $9.27M $10.32M $426.00K $369.00K $280.00K $327.00K
Total Assets $913.17M $904.95M $907.44M $966.74M $910.43M $991.12M $964.32M
Accounts Payable $22.16M $31.24M $32.00M $28.49M $27.51M $31.69M $20.42M
Accrued Liabilities $111.16M - - - $81.94M $74.82M $61.79M
Total Current Liabilities $138.36M $125.78M $129.16M $122.69M $122.34M $118.06M $93.64M
Deferred Tax Liabilities $31.83M $31.66M $34.70M $31.96M $32.31M $32.22M $31.90M
Total Liabilities $214.59M $202.66M $208.95M $198.88M $200.02M $217.66M $195.78M
Common Stock $17.00K $16.00K $14.00K $14.00K $13.00K $13.00K $12.00K
Retained Earnings $-2.78B $-2.70B $-2.61B $-2.50B $-2.38B $-2.31B $-2.22B
Total Stockholders Equity $698.58M $702.29M $698.49M $767.87M $710.40M $773.46M $768.54M
Total Liabilities & Equity $913.17M $904.95M $907.44M $966.74M $910.43M $991.12M $964.32M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $-71.90M $-91.25M $-227.82M $-116.16M $-78.56M $-83.54M $-210.08M
Depreciation & Amortization $3.72M $9.14M $3.40M $2.79M $3.27M $8.99M $5.96M
Stock-based Compensation $11.82M $11.90M $37.86M $22.91M $30.98M $78.65M $47.64M
Deferred Income Tax $184.00K $-2.25M $150.00K $-1.84M $1.56M $-4.39M $-2.87M
Change in Receivables $15.69M $-2.58M $-9.40M $1.60M $13.57M $55.62M $31.45M
Change in Inventory $4.00M $10.21M $7.03M $13.97M $18.93M $26.47M $15.59M
Change in Payables $-5.21M $-1.45M $2.94M $2.05M $-6.07M $-1.77M $-16.20M
Operating Cash Flow $-52.56M $-249.84M $-171.14M $-103.69M $-73.30M $-279.68M $-220.71M
Capital Expenditure $9.32M $24.52M $13.67M $6.21M $4.17M $6.90M $4.61M
Acquisitions - - - - - - $52.57M
Investing Cash Flow $775.00K $46.72M $29.71M $15.87M $23.68M $-120.09M $-71.29M
Stock Issued $55.78M $250.53M $162.01M $148.94M - $397.30M $349.79M
Financing Cash Flow $56.17M $244.60M $156.54M $143.31M $2.31M $388.36M $346.40M
Net Change in Cash $4.96M $42.05M $16.36M $56.00M $-48.49M $-10.78M $53.79M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $67.45M $58.55M $176.73M $90.38M
Cost of Revenue $38.48M $31.52M $130.07M $55.46M
Operating Expenses $162.36M $147.62M $506.63M $399.08M
Research & Development $75.17M $67.04M $229.07M $205.22M
Operating Income $-94.90M $-89.07M $-329.90M $-308.70M
Interest Income $1.24M $4.00M $8.57M $10.70M
Income Before Tax $-93.66M $-85.06M $-321.33M $-298.00M
Income Tax Expense $-2.40M $-1.52M $-2.25M $-4.39M
Net Income $-91.25M $-83.54M $-319.07M $-293.62M
Basic EPS -0.25 -0.28 -0.94 -1.03
Basic Shares Outstanding $364.04K $303.27K $340.62K $284.84K
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $158.13M $115.69M
Short-term Investments $142.67M $208.09M
Accounts Receivable $66.76M $69.34M
Inventory $51.71M $51.52M
Other Current Assets $9.82M $12.38M
Total Current Assets $429.09M $457.02M
Property Plant & Equipment $126.65M $109.08M
Intangible Assets $285.21M $282.40M
Other Non-current Assets $9.27M $369.00K
Total Assets $904.95M $910.43M
Accounts Payable $31.24M $27.51M
Total Current Liabilities $125.78M $122.34M
Deferred Tax Liabilities $31.66M $32.31M
Total Liabilities $202.66M $200.02M
Common Stock $16.00K $13.00K
Retained Earnings $-2.70B $-2.38B
Total Stockholders Equity $702.29M $710.40M
Total Liabilities & Equity $904.95M $910.43M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-91.25M $-83.54M $-319.07M $-293.62M
Depreciation & Amortization $9.01M $9.73M $9.14M $7.98M
Stock-based Compensation $11.90M $31.01M $49.76M $78.65M
Deferred Income Tax - - $-2.25M $-4.39M
Change in Receivables - - $-2.58M $55.62M
Change in Inventory - - $10.21M $25.45M
Change in Payables - - $-1.45M $-1.77M
Operating Cash Flow - - $-249.84M $-279.68M
Capital Expenditure - - $24.52M $6.90M
Investing Cash Flow - - $46.72M $-120.09M
Stock Issued - - $250.53M $397.30M
Financing Cash Flow - - $244.60M $388.36M
Net Change in Cash - - $42.05M $-10.78M

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...